Top Markets
#1 龙虾 (Lobster) 龙虾 (Lobster) +117.81%
#2 Lisk Lisk +81.56%
#3 Not in Employment, Education, or Training Not in Employment, Education, or Training +30.37%
#4 Tokenlon Tokenlon +28.92%
#5 Alchemist AI Alchemist AI +28.02%
#6 Nockchain Nockchain +25.68%
#7 earnAUSD earnAUSD +24.75%
#8 Renzo Renzo +21.89%
#9 Illuvium Illuvium +19.74%
#10 Akedo Akedo +18.38%
Coin of the day
龙虾 (Lobster) 龙虾 (Lobster)
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
MultiCell Technologies, Inc. MultiCell Technologies, Inc.

MultiCell Technologies, Inc.

MCET
Classement en actions #41009
MultiCell Technologies, Inc. (MCET) operates as a biopharmaceutical firm,... MultiCell Technologies, Inc. (MCET) operates as a biopharmaceutical firm, primarily focused on the creation of innovative therapeutic agents and research tools. Their efforts are directed towards addressing a range of medical challenges, including neurological conditions, liver ailments, various types of cancer, and applications within interventional cardiology and peripheral vascular health. The company's product pipeline features several key developments: MCT-125: This investigational therapy is currently in Phase II clinical trials, targeting the primary fatigue commonly associated with multiple sclerosis. MCT-465: A preclinical-stage synthetic double-stranded RNA (dsRNA) candidate, designed to act as a powerful immune enhancer for the treatment of solid tumor malignancies. MCT-485: Another dsRNA therapeutic, still in the discovery phase, which demonstrates tumor cytolytic (cell-destroying) properties, intended for use against diverse cancers. Beyond drug candidates, MultiCell Technologies is also progressing the Ideal BioStent, an innovative bioabsorbable stent specifically engineered for use in interventional cardiology and peripheral vessel procedures. The organization maintains licensing agreements with prominent entities such as Corning Incorporated and Pfizer Inc. Established in 1962, the company was previously known as Exten Industries, Inc. before officially changing its name to MultiCell Technologies, Inc. in April 2004. Its corporate headquarters are situated in Woonsocket, Rhode Island.
Prix de l'action
$0.00001
Dernière synchronisation: 2026-09-10
Capitalisation boursière
$50.01K
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange MultiCell Technologies, Inc. (MCET)

Catégorie

Healthcare
Revenus pour MultiCell Technologies, Inc. (MCET)
Revenus en Aug 2015 TTM : $805.24
Selon les derniers rapports financiers de MultiCell Technologies, Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de $805.24. En 2013, l'entreprise a réalisé un chiffre d'affaires de $49.32 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour MultiCell Technologies, Inc. de 2013 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
2026 (TTM) $805.24 1,532.68%
2014 $49.32 0.00%
2013 $49.32 0.00%
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 1,567,776,303.44%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 747,766,680.05%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 276,688,970.04%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B 1,955,243,721.94%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH